AK104 in Neoadjuvant Treatment of Cervical Cancer
NCT05227651 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 14
Last updated 2024-11-01
Summary
Phase II open label study to evaluate the safety and efficacy of AK104 (anti-PD-1 and CTLA-4 bispecific antibody) in neoadjuvant treatment of cervical cancer.
Conditions
Interventions
- DRUG
-
AK104
IV infusion,Specified dose on specified days
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-02-10
- Primary Completion
- 2024-09-27
- Completion
- 2024-09-27
Countries
- China
More Related Trials
-
Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix
NCT05063916 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Phase II Study on Neoadjuvant Therapy of AK104 Combined With Nab-paclitaxel/Carboplatin in Fertility Preserving Surgery
NCT06209294 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of Concurrent Chemoradiotherapy Followed by Cadonilimab（AK104） for Newly Diagnosed Local Advanced Cervical Cancer
NCT06251388 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
NCT04982237 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Neoadjuvant Immunochemotherapy for Locally Advanced Cervical Cancer: a Prospective, Single-arm, Phase II Clinical Trial
NCT07003620 ·Status: RECRUITING ·Phase: PHASE2
-
AK104 Combined With I-125 Brachytherapy for Recurrent or Metastatic Cervical Cancer
NCT06062589 ·Status: NOT_YET_RECRUITING
-
Cadonilimab Plus Nab -Paclitaxel for Patients With Recurrent, or Metastatic Cervical Cancer Resistant to Immune Checkpoint Inhibitors
NCT05824494 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Evaluation of AK104 (Cadonilimab) Combined with Chemotherapy for Recurrent or Metastatic Small Cell Neuroendocrine Carcinoma of the Cervix
NCT06810895 ·Status: ENROLLING_BY_INVITATION
-
AK105 Combined With Anlotinib in Patients With Cervical Cancer
NCT05137171 ·Status: UNKNOWN ·Phase: PHASE2
-
A Phase Ⅱ Study of F520 in Patients With Cervical Carcinoma
NCT06226350 ·Status: COMPLETED ·Phase: PHASE2
-
Neoadjuvant Immunochemotherapy in PD-L1-negative LACC
NCT06288360 ·Status: RECRUITING ·Phase: PHASE2
-
A Single-Arm, Phase II Clinical Trail of Cadonilimab Combined With Chemoradiotherapy in Oligometastatic Stage IVB Cervical Cancer
NCT06998394 ·Status: RECRUITING ·Phase: PHASE2
-
Donafenib for Recurrent Cervical Cancer
NCT05310331 ·Status: UNKNOWN ·Phase: PHASE2
-
Neoadjuvant Chemo-immunotherapy Followed by Concurrent Chemoradiotherapy and Immunotherapy in LACC
NCT06916117 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Study of Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer
NCT03469531 ·Status: UNKNOWN ·Phase: PHASE2
-
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
NCT02257528 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Clinical Study of Albumin-bound Paclitaxel Plus Nedaplatin in Cervical Cancer
NCT01667211 ·Status: UNKNOWN ·Phase: PHASE2
-
Phase II Clinical Trial of Concurrent Chemoradiotherapy Combined Nimotuzumab for Stage IIB-IVA Cervical Cancer
NCT02705612 ·Status: UNKNOWN ·Phase: PHASE2
-
Low-dose Pembrolizumab Plus Chemotherapy for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer.
NCT06670911 ·Status: RECRUITING ·Phase: PHASE2
-
A Clinical Trial to Assess PVX7 Immunotherapy Regimens in Advanced Cervical Cancer Patients
NCT06315257 ·Status: RECRUITING ·Phase: PHASE1
-
Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer
NCT04375384 ·Status: RECRUITING ·Phase: PHASE2
-
A Phase II, Single-arm, Multicenter, Prospective Study of Cardunolizumab in Recurrent or Metastatic Vulvar and Vaginal Cancer
NCT06292689 ·Status: RECRUITING ·Phase: PHASE2
-
Concurrent Chemoradiotherapy Combined With Adjuvant Chemotherapy Treated Advanced Cervical Cancer
NCT05735145 ·Status: RECRUITING ·Phase: PHASE3
-
Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas
NCT04635956 ·Status: UNKNOWN ·Phase: PHASE2
-
Neoadjuvant Treatment of Neuroendocrine Cervix Carcinomar With Camrelizumab Combined With Etoposide and Cisplatin
NCT05910177 ·Status: RECRUITING ·Phase: PHASE2